Kailera Therapeutics, Inc. Net Fee Amt
Kailera Therapeutics, Inc. (KLRA) had Net Fee Amt of $98.66 thousand as of 2026-04-16, per its S-8 filed 2026-04-17.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-17
- 2026-04-16: Net Fee Amt $98.66K; Net Fee Amt as first filed $14.56K.
- 2026-04-10: Net Fee Amt $70.89K.
| Period end | Net Fee Amt | Net Fee Amt as first filed |
|---|---|---|
| 2026-04-16 | $98.66K S-8 · filed 2026-04-17 | $14.56K S-1MEF · filed 2026-04-16 |
| 2026-04-10 | $70.89K S-1/A · filed 2026-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |